Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for
decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic
chemotherapy. Intraperitoneal chemotherapy in combination with systemic chemotherapy is under
many clinical trials mainly in Japan, and are showing promising results.
This is Korea's first clinical trial on Intraperitoneal Paclitaxel with Systemic mFOLFOX6
chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborators:
B. Braun Korea Co., Ltd. Boryung Pharmaceutical Co., Ltd